Related Experiment Video
Updated: Aug 21, 2026
Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
Published on: October 10, 2025
The biology of non-small-cell lung cancer: identifying new targets for rational therapy
R Rosell1, E Felip, R Garcia-Campelo
1Medical Oncology Service, Hospital Germans Trias i Pujol, Ctra Canyet, s/n 08916 Barcelona, Spain. rrosell@ns.hugtip.scs.es
Abstract:
Lung cancer, and in particular non-small-cell lung cancer (NSCLC), remains the leading cause of cancer death throughout the world. Almost three decades ago, the major concern was to identify whether cisplatin or cisplatin-based chemotherapy enhanced survival in metastatic NSCLC, and whether any survival benefit compensated for cisplatin-related toxicity. Over the last 10 years, significant advances have been achieved in molecular biology, including the identification of critical genes related to the pathogenesis of NSCLC, which have formed the basis for new targeted therapeutic approaches. These new approaches include novel agents against established chemotherapeutic targets such as thymidylate synthetase as well as agents that inhibit novel targets such as growth factor receptors and proteins important in angiogenesis. With the advent of genomic technologies that can identify patterns of gene expression, the hope is that therapy will be tailored to the genetic pattern of the patients's tumor, and individualized treatments that minimize toxicity and maximize efficacy can be developed.
Insights
Lung cancer remains a major global health concern. Advances in molecular biology are paving the way for targeted therapies and individualized treatments for non-small-cell lung cancer (NSCLC) to improve efficacy and minimize toxicity.
Area of Science:
- Oncology
- Molecular Biology
- Genomics
Background:
- Non-small-cell lung cancer (NSCLC) is a leading cause of cancer mortality worldwide.
- Historically, treatment focused on cisplatin-based chemotherapy for metastatic NSCLC, balancing survival benefits against toxicity.
- Recent molecular biology advances have identified key genes in NSCLC pathogenesis, enabling new therapeutic strategies.
Purpose of the Study:
- To review the evolution of lung cancer treatment strategies.
- To highlight the impact of molecular biology and genomic technologies on NSCLC therapy.
- To discuss the development of targeted therapies and personalized medicine approaches for NSCLC.
Main Methods:
- Review of historical and recent literature on NSCLC treatment.
- Analysis of advances in molecular biology and genetic profiling.
- Discussion of novel therapeutic targets and genomic technologies.
Main Results:
- Significant progress in understanding NSCLC pathogenesis through molecular biology.
- Identification of novel therapeutic targets, including growth factor receptors and angiogenesis proteins.
- Emergence of genomic technologies for personalized treatment strategies.
Conclusions:
- Targeted therapies and individualized treatments hold promise for improving NSCLC outcomes.
- Genomic profiling enables tailoring treatments to a patient's tumor genetic patterns.
- Future NSCLC therapy aims to maximize efficacy while minimizing treatment-related toxicity.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:39lncRNA - Long Non-coding RNAs
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...